Dale T. Umetsu is an American academic physician, immunologist and pharmaceutical executive, who currently serves as clinical professor of medicine at Stanford University and clinical professor of pediatrics at the University of California, San Francisco.[1][2][3] Previously, he served as the Prince Turki bin Abdul Aziz al-Saud Professor of Pediatrics at Harvard Medical School and as a tenured professor of pediatrics at Stanford University.[4][5][6]
Dale T. Umetsu | |
|---|---|
| Nationality | American |
| Occupation(s) | Academic physician, immunologist and pharmaceutical executive |
| Academic background | |
| Education | Columbia University (BA) New York University (MD and PhD) |
| Academic work | |
| Discipline | Immunology Translational medicine |
| Institutions | Harvard Medical School Boston Children's Hospital Stanford University University of California, San Francisco |
Biography
editUmetsu earned a Bachelor of Arts in biochemistry from Columbia University, followed by an MD and PhD in medicine and immunology from New York University.[7][8] He completed his residency at Boston Children's Hospital, affiliated with Harvard Medical School.[7][8]
Umetsu began his academic career at Stanford University as a professor, where he also served as the director of the Asthma Center.[7]
In 2005, Umetsu joined Harvard Medical School as the Prince Turki Bin Abdul Aziz al Saud Professor of Pediatrics and conducted NIH-funded laboratory research for over two decades.[7][9] His roles included Treasurer of the Society for Mucosal Immunology from 2007 to 2011, a member of the editorial board of Mucosal Immunology since 2008, and associate editor from 2009 onwards.[10] He also served on the board of the American Academy of Allergy and Immunology from 2002 to 2007, as a member of the Allergenic Products Advisory Committee at CBER FDA from 1998 to 2002, and as a Study Section chair with the Center for Scientific Review from 1998 to 2000.
In 2013, Umetsu transitioned from academia to the role of Principal Medical Director in Respiratory and Allergic Diseases and Global Development Lead for Xolair at Genentech.[7]
Research
editUmetsu's research primarily focuses on the immunobiology of allergic diseases and asthma, focusing on subsets of CD4 T cells, Natural killer T cells, Treg cells, innate lymphoid cells and the TIM gene family. He has published over 200 manuscripts, holds nine patents, and has been working in translational medicine in asthma and food allergies.[11][7]
Umetsu's research has shown that omalizumab, an anti-IgE monoclonal antibody, marketed as Xolair by Genentech, can significantly mitigate allergic reactions in individuals with severe food allergies.[12] These studies led to his role at Genentech, as Principal Medical Director and Global Development Lead, where he led efforts that culminated in a successful Phase 3 study (a collaboration between Genentech and the NIH) and subsequent FDA approval of omalizumab for food allergy in 2024.[13]
In 2004, Umetsu led a team that developed vaccines that reduced or eliminated dogs' allergic reactions to peanuts, milk, and wheat.[14] Umetsu's approach, using heat-killed Listeria mixed with allergens, _targets the hygiene hypothesis.[15]
References
edit- ^ "Meet Our Team | Giving to Broad Institute of MIT and Harvard". giving.broadinstitute.org.
- ^ https://www.seattlepi.com/lifestyle/health/article/promising-vaccine-could-cure-common-food-allergies-1159403.php
- ^ "UCSF Directory". directory.ucsf.edu.
- ^ "Immunology Faculty Member - Dale Umetsu". December 7, 2013. Archived from the original on 2013-12-07.
- ^ https://hms.harvard.edu/news/new-treatment-peanut-allergies
- ^ https://www.npr.org/transcripts/5286340?storyId=5286340?storyId=5286340
- ^ a b c d e f "Dale Umetsu".
- ^ a b "News & Highlights". Mucosal Immunology. 1 (3): 170–171. May 1, 2008. doi:10.1038/mi.2008.10 – via Nature.
- ^ "New treatment may desensitize kids with milk allergies, study suggests". ScienceDaily.
- ^ "News & Highlights". Mucosal Immunology. 1 (3): 170–171. May 1, 2008. doi:10.1038/mi.2008.10 – via www.nature.com.
- ^ "Umetsu DT - Search Results - PubMed". PubMed.
- ^ Schneider, Lynda C.; Rachid, Rima; LeBovidge, Jennifer; Blood, Emily; Mittal, Mudita; Umetsu, Dale T. (December 21, 2013). "A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients". The Journal of Allergy and Clinical Immunology. 132 (6): 1368–1374. doi:10.1016/j.jaci.2013.09.046. PMC 4405160. PMID 24176117.
- ^ Commissioner, Office of the (August 9, 2024). "FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure". FDA.
- ^ Pallarito, Karen (November 12, 2004). "Vaccine Stops Food Allergy in Dogs". www.healthday.com.
- ^ https://www.seattlepi.com/lifestyle/health/article/Promising-vaccine-could-cure-common-food-allergies-1159403.php